Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17931191 | 0.80 | GAA (0.54) | GAAL3MBTL1ALDH1A1 | |
| SCHEMBL4853121 | 0.78 | GAA (0.52) | GAAL3MBTL1 | |
| SCHEMBL12846238 | 0.78 | GAA (0.52) | GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4960439 | 0.77 | GAA (0.50) | GAAL3MBTL1 | |
| SCHEMBL14924878 | 0.77 | GAA (0.50) | GAAL3MBTL1 | |
| SCHEMBL14924253 | 0.77 | GAA (0.50) | GAAL3MBTL1 | |
| SCHEMBL1932618 | 0.77 | GAA (0.50) | GAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4436968 | 0.75 | GAA (0.48) | GAAL3MBTL1 | |
| SCHEMBL6558988 | 0.75 | GAA (0.48) | GAAL3MBTL1 | |
| SCHEMBL12846368 | 0.73 | GAA (0.47) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2007123818-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007016136-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITONS AND METHODS OF USE | NITROMED, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048219-A1 | ORGANIC NITRIC OXIDE DONOR SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS3, NOS1, NOS2 | GAA 4607/4885L3MBTL1 3793/4885ALDH1A1 630/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | GAA 1892/4885L3MBTL1 3906/4885ALDH1A1 1240/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | GAA 1190/4885L3MBTL1 3552/4885ALDH1A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.